Perspective | Published:

Consensus recommendations for the role and competencies of the EBMT clinical pharmacist and clinical pharmacologist involved in hematopoietic stem cell transplantation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Mahajan S, Tandon N, Kumar S. The evolution of stem-cell transplantation in multiple myeloma. Ther Adv Hematol. 2018;9:123–33.

  2. 2.

    McDonald-Hyman C, Turka LA, Blazar BR. Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation. Sci Transl Med. 2015;7:280rv282

  3. 3.

    Bauters T, Vinent-Genestar J, Delaney J, Mycroft J, Vandenbroucke J. Role of the clinical pharmacist in a paediatric haemato-oncology stem cell transplantation ward. Eur J Hosp Pharm. 2014;21:309–12.

  4. 4.

    Clemmons AB, Alexander M, DeGregory K, Kennedy L. The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group. Biol Blood Marrow Transpl. 2018;24:914–22.

  5. 5.

    Bryk A, Koontz S, Mayor J, Betcher J, Tombleson R, Bookout R et al. Characterization of collaborative practice agreements held by hematopoietic stem cell transplant pharmacists. J Oncol Pharm Pract. 2017.

  6. 6.

    FACT-JACIE International Standards for Hematopoietic Cellular Therapy. In. 7 edn, 2018. Accessed 14 May 2019.

  7. 7.

    Yuksel MK, Ilhan O. JACIE: A 20 year-old voluntary body functioning worldwide. Transfus Apher Sci. 2018;57:153–8.

  8. 8.

    EBMT Pharmacist Committee., accessed 24 April 2019).

  9. 9.

    Rudis MI, Brandl KM. Position paper on critical care pharmacy services. Society of Critical Care Medicine and American College of Clinical Pharmacy Task Force on Critical Care Pharmacy Services. Crit Care Med. 2000;28:3746–50.

  10. 10.

    Saseen JJ, Ripley TL, Bondi D, Burke JM, Cohen LJ, McBane S, et al. ACCP Clinical Pharmacist Competencies. Pharmacotherapy. 2017;37,:630–6.

  11. 11.

    Fernandes O, Gorman SK, Slavik RS, Semchuk WM, Shalansky S, Bussieres JF, et al. Development of clinical pharmacy key performance indicators for hospital pharmacists using a modified Delphi approach. Ann Pharm. 2015;49:656–69.

  12. 12.

    Leape LL, Cullen DJ, Clapp MD, Burdick E, Demonaco HJ, Erickson JI, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999;282:267–70.

  13. 13.

    Bond CA, Raehl CL. Clinical pharmacy services, pharmacy staffing, and hospital mortality rates. Pharmacotherapy. 2007;27:481–93.

  14. 14.

    Bond CA, Raehl CL. Clinical pharmacy services, pharmacy staffing, and adverse drug reactions in United States hospitals. Pharmacotherapy. 2006;26:735–47.

  15. 15.

    Viktil KK, Blix HS. The impact of clinical pharmacists on drug-related problems and clinical outcomes. Basic Clin Pharmacol Toxicol. 2008;102:275–80.

  16. 16.

    Schumock GT, Butler MG, Meek PD, Vermeulen LC, Arondekar BV, Bauman JL. Evidence of the economic benefit of clinical pharmacy services: 1996-2000. Pharmacotherapy. 2003;23:113–32.

  17. 17.

    Rotta I, Salgado TM, Silva ML, Correr CJ, Fernandez-Llimos F. Effectiveness of clinical pharmacy services: an overview of systematic reviews (2000-2010). Int J Clin Pharm. 2015;37:687–97.

  18. 18.

    Touchette DR, Doloresco F, Suda KJ, Perez A, Turner S, Jalundhwala Y, et al. Economic evaluations of clinical pharmacy services: 2006-2010. Pharmacotherapy. 2014;34:771–93.

  19. 19.

    Langebrake C, Ihbe-Heffinger A, Leichenberg K, Kaden S, Kunkel M, Lueb M, et al. Nationwide Evaluation of Day-to-Day Clinical Pharmacists’ Interventions in German Hospitals. Pharmacotherapy. 2015;35:370–9.

  20. 20.

    Langebrake C, Hilgarth H. Clinical pharmacists’ interventions in a German university hospital. Pharm World Sci. 2010;32:194–199.

  21. 21.

    FIP Global Conference on the Future of Hospital Pharmacy—Final Basel Statements. 2008. Accessed 14 May 2019.

  22. 22.

    The European Statements of Hospital Pharmacy. Eur J Hosp Pharm. 2014; 21, 256–8. Accessed 14 May 2019.

  23. 23.

    Gillaizeau F, Chan E, Trinquart L, Colombet I, Walton R, Rege-Walther M et al. Computerized advice on drug dosage to improve prescribing practice. Cochrane Database Syst Rev 2013; 11: CD002894. e-pub ahead of print 2013/11/13;

  24. 24.

    Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, et al. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016;3:e526–e536.

  25. 25.

    Andersson BS, Valdez BC. Pretransplant conditioning with fludarabine and IV busulfan, reduced toxicity and increased safety without compromising antitumor efficacy and overall treatment effect? Bone Marrow Transpl. 2016;51:919–20.

  26. 26.

    Admiraal R, Nierkens S, de Witte MA, Petersen EJ, Fleurke GJ, Verrest L, et al. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis. Lancet Haematol. 2017;4:e183–e191.

  27. 27.

    Admiraal R, van Kesteren C, Jol-van der Zijde CM, Lankester AC, Bierings MB, Egberts TC, et al. Association between anti-thymocyte globulin exposure and CD4+immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. Lancet Haematol. 2015;2:e194–203.

  28. 28.

    Lempers VJ, Martial LC, Schreuder MF, Blijlevens NM, Burger DM, Aarnoutse RE, et al. Drug-interactions of azole antifungals with selected immunosuppressants in transplant patients: strategies for optimal management in clinical practice. Curr Opin Pharm. 2015;24:38–44.

  29. 29.

    Langenhorst JB, Dorlo TPC, van Maarseveen EM, Nierkens S, Kuball J, Boelens JJ et al. Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. Clin Pharmacokinet. 2018.

  30. 30.

    Long-Boyle JR, Green KG, Brunstein CG, Cao Q, Rogosheske J, Weisdorf DJ, et al. High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. Bone Marrow Transpl. 2011;46:20–26.

  31. 31.

    Hilken A, Langebrake C, Wolschke C, Kersten JF, Rohde H, Nielsen P et al. Impact of non-transferrin-bound iron (NTBI) in comparison to serum ferritin on outcome after allogeneic stem cell transplantation (ASCT). Ann Hematol. 2017;96:1379–1388.

  32. 32.

    Admiraal R, van Kesteren C, Boelens JJ, Bredius RG, Tibboel D, Knibbe CA. Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling. Arch Dis Child. 2014;99:267–72.

  33. 33.

    McCune JS, Bemer MJ, Long-Boyle J. Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II. Clin Pharmacokinet. 2016;55:551–93.

  34. 34.

    McCune JS, Bemer MJ. Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I. Clin Pharmacokinet. 2016;55:525–50.

  35. 35.

    Brill MJ, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CA. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51:277–304.

  36. 36.

    Langebrake C, Bernhardt F, Baehr M, Kroger N, Zander AR. Drug dosing and monitoring in obese patients undergoing allogenic stem cell transplantation. Int J Clin Pharm. 2011;33:918–24.

  37. 37.

    Admiraal R, Boelens JJ. Individualized conditioning regimes in cord blood transplantation: Towards improved and predictable safety and efficacy. Expert Opin Biol Ther. 2016;16:801–13.

  38. 38.

    Krekels EHJ, van Hasselt JGC, van den Anker JN, Allegaert K, Tibboel D, Knibbe CAJ. Evidence-based drug treatment for special patient populations through model-based approaches. Eur J Pharm Sci: Off J Eur Fed Pharm Sci. 2017;109S:S22–S26.

  39. 39.

    Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston L, Patnaik MM, et al. Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. J Clin Oncol. 2017;35:4003–11.

  40. 40.

    Ho L, Akada K, Messner H, Kuruvilla J, Wright J, Seki JT. Pharmacist’s Role in Improving Medication Safety for Patients in an Allogeneic Hematopoietic Cell Transplant Ambulatory Clinic. Can J Hosp Pharm. 2013;66:110–7.

  41. 41.

    Warholak TL, West D, Holdford DA. The Educating Pharmacy Students and Pharmacists to Improve Quality program: tool for pharmacy practice. J Am Pharm Assoc: JAPhA. 2010;50:534–8.

  42. 42.

    Passweg JR, Baldomero H, Bader P, Basak GW, Bonini C, Duarte R, et al. Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transpl. 2018;53:1139–48.

  43. 43.

    Khera N, Zeliadt SB, Lee SJ. Economics of hematopoietic cell transplantation. Blood. 2012;120:1545–51.

  44. 44.

    Dalton K, Byrne S. Role of the pharmacist in reducing healthcare costs: current insights. Integr Pharm Res Pr. 2017;6:37–46.

  45. 45.

    Beck JC, Chen B, Gordon BG. Physician approaches to drug shortages: Results of a national survey of pediatric hematologist/oncologists. World J Clin Oncol. 2017;8:336–42.

  46. 46.

    Leache L, Aquerreta I, Aldaz A, Idoate A, Ortega A. Evidence of clinical and economic impact of pharmacist interventions related to antimicrobials in the hospital setting. Eur J Clin Microbiol Infect Dis. 2018;37:799–822.

  47. 47.

    Solano C, Slavin M, Shaul AJ, Marks DI, Cordonnier C, Cornely OA, et al. Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant. Mycoses. 2017;60:79–88.

  48. 48.

    Mohty M, Azar N, Chabannon C, Le Gouill S, Karlin L, Farina L, et al. Plerixafor in poor mobilizers with non-Hodgkin’s lymphoma: a multi-center time-motion analysis. Bone Marrow Transpl. 2018;53:246–54.

  49. 49.

    Rubio-Terres C, Cobo Reinoso J, Grau Cerrato S, Mensa Pueyo J, Salavert Lleti M, Toledo A, et al. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain. Eur J Clin Microbiol Infect Dis. 2015;34:2213–23.

Download references

Author information

Correspondence to Claudia Langebrake.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Members of the EBMT Working Group are listed at the end of the paper.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark